Clinical Pharmacokinetics of Cholinesterase Inhibitors (original) (raw)
Aeschlimann J, Reinert M. Pharmacological action of some analogues of physostigmine. Journal of Pharmacology and Experimental Therapeutics 43: 413–444, 1931 CAS Google Scholar
Albanus L. Studies on central and peripheral effects of anticholinergic drugs. FOA Reports 4: 3–17, 1970 Google Scholar
Alridge WN, Holmstedt B. History and scope of the conference. Acta Pharmacologica et Toxicologica 49 (Suppl. V): 3–6, 1981 Google Scholar
Aquilonius S-M, Askmark H, Eckernäs S-Å, Gillberg P-G, Hilton-Brown P, et al. Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis: A controlled study of physostigmine versus neostigmine. Acta Neurologica Scandinavica, in press, 1985 Google Scholar
Aquilonius S-M, Eckernäs S-Å, Hartvig P, Hultman J, Lindström B, et al. Selective and sensitive determination of plasma neostigmine using gas chromatography-mass spectrometry: basic pharmacokinetics in man. Acta Neurologica Scandinavica 57:(Suppl. 67): 271–272, 1978 Google Scholar
Aquilonius S-M, Eckernäs S-Å, Hartvig P, Hultman J, Lindström B, et al. A pharmacokinetic study of neostigmine in man using gas chromatography-mass spectrometry. European Journal of Clinical Pharmacology 15: 367–371, 1979 ArticlePubMedCAS Google Scholar
Aquilonius S-M, Eckernäs, S-Å, Hartvig P, Lindström B, Osterman PO. Pharmacokinetics and oral bioavailability of pyridostigmine in man. European Journal of Clinical Pharmacology 48: 423–428, 1980 Article Google Scholar
Aquilonius S-M, Eckernäs S-Å, Hartvig P, Lindström B, Osterman PO, et al. Clinical pharmacology of neostigmine and pyridostigmine in patients with myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry 46: 929–935, 1983 ArticleCAS Google Scholar
Aquilonius S-M, Hedstrand U. The use of physostigmine as an antidote in tricyclic anti-depressant intoxication. Acta Anaesthesiologica Scandinavica 22: 40–45, 1978 ArticlePubMedCAS Google Scholar
Aquilonius S-M, Sjöström R. Cholinergic and dopaminergic mechanisms in Huntington’s chorea. Life Sciences 10: 405–414, 1971 ArticleCAS Google Scholar
Axelsson U. Glaucoma miotic therapy and cataract: studies on ecothiopate (Phospholine Iodide) and paraoxon (Mintacol) with regard to cataractogenic effect. Acta Ophthalmologica (Kbh) Suppl. 102: 1–11, 1969 Google Scholar
Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin. Pharmacol. Therap. 37: 495–501, 1985 ArticleCAS Google Scholar
Calvey TN, Chan K. Plasma pyridostigmine levels in patients with myasthenia gravis. Clinical Pharmacology and Therapeutics 21: 187–193, 1977 PubMedCAS Google Scholar
Calvey TN, Chan K, Dehghan A, Williams NE. Kinetics of intravenous pyridostigmine in man. British Journal of Clinical Pharmacology 11: 406–407, 1981 ArticlePubMedCAS Google Scholar
Calvey TN, Wareing M, Williams NE, Chan K. Pharmacokinetics and pharmacological effects of neostigmine in man. British Journal of Clinical Pharmacology 7: 149–155, 1978 Article Google Scholar
Calvey TN, Williams NE, Muir KT, Barber HE. Plasma concentration of edrophonium in man. Clinical Pharmacology and Therapeutics 19: 813–820, 1976 PubMedCAS Google Scholar
Chan K, Calvey TN. Renal clearance of pyridostigmine in patients with myasthenia gravis. Europ. J. Neurol. 16: 69–72, 1977 ArticleCAS Google Scholar
Chan K, Calvey TN. Plasma concentration of pyridostigmine and effects in myasthenia gravis. Clinical Pharmacology and Therapeutics 22: 596–601, 1978 Google Scholar
Chan K, Davison SC, Dehghan A, Hyman N. The effect of neostigmine and pyridostigmine bioavailability in myasthenic patients after oral administration. Methods and Findings in Experimental Clinical Pharmacology 3: 291–296, 1981 CAS Google Scholar
Chan K, Dehghan A. The isolation and determination of neostigmine and pyridostigmine and their metabolites in human biological fluids. J. Pharmacol. Meth. 1: 311–320, 1978 ArticleCAS Google Scholar
Chan K, Williams NE, Baty JD, Calvey TN. A quantitative gas-liquid Chromatographic method for the determination of neostigmine and pyridostigmine in human plasma. Journal of Chromatography 120: 349–358, 1976 ArticlePubMedCAS Google Scholar
Cohan SL, Drettchen KL, Neal A. Malabsorption of pyridostigmine in patients with myasthenia gravis. Neurology 27: 299–301, 1977 ArticlePubMedCAS Google Scholar
Cohan SL, Pohlman JLW, Mikszewski J, O’Doherty DS. The pharmacokinetics of pyridostigmine. Neurology 26: 536–539, 1976 ArticlePubMedCAS Google Scholar
Coper H, Deyhle G, Dross K. Studies on the absorption of pyridostigmine: the application of a spectrometric method for the determination of pyridostigmine in plasma. Zeitung Klinische Chemische und Klinische Biochemie 12: 273–275, 1974 CAS Google Scholar
Cronnelly R, Morris RB. Antagonism of neuromuscular blockade. British Journal of Anaesthesia 54: 183–194, 1982 ArticlePubMedCAS Google Scholar
Cronnelly R, Stanski DR, Miller RD. Pyridostigmine kinetics with and without renal failure. Clinical Pharmacology and Therapeutics 28: 78–81, 1980 ArticlePubMedCAS Google Scholar
Cronnelly R, Stanski DR, Miller RD, Seheiner LB, Sohn YJ. Renal function and the pharmacokinetics of neostigmine in anaesthetized man. Anaesthesiology 51: 222–226, 1979 ArticleCAS Google Scholar
Daunderer M. Physostigmine salicylate as an antidote. International Journal of Clinical Pharmacology, Therapy and Toxicology 18: 523–535, 1980 CAS Google Scholar
Davison SC, Hyman NM, Delighan A, Chan K. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry 44: 1141–1145, 1981 ArticleCAS Google Scholar
DeRuyter MGM, Cronnelly R, Castagnoli N. Reversed phase, ion pair liquid chromatography of quaternary ammonium compounds. Determination of pyridostigmine, neostigmine and edrophonium in biological fluids. Journal of Chromatography 183: 193–201, 1980 ArticleCAS Google Scholar
Duvoisin RC. Cholinergic-anticholinergic antagonism in Parkinsonism. Archives of Neurology 17: 124–136, 1967 ArticlePubMedCAS Google Scholar
Ellin RI, Zvirblis P, Wilson MR. Method for isolation and determination of pyridostigmine and metabolites in urine and blood. Journal of Chromatography 228: 235–244, 1982 ArticlePubMedCAS Google Scholar
Fisher DM, Cronnelly R, Miller RD, Sharma M. The neuromuscular pharmacology of neostigmine in infants and children. Anesthesiology 59: 220–225, 1983 ArticlePubMedCAS Google Scholar
Fisher DM, Cronnelly R, Miller RD, Sharma M. The clinical pharmacology of edrophonium in infants and children. Anesthesiology 61: 428–433, 1984 ArticlePubMedCAS Google Scholar
Fraser TR. On atropia as a physiological antidote to the poisonous effects of physostigma. Practitioner (London) 4: 65–72, 1870 Google Scholar
Gibson M, Moore T, Smith CM, Whelpton R. Physostigmine concentrations after oral doses. Lancet 1: 695–696, 1985 ArticlePubMedCAS Google Scholar
Hardell L-J, Lindström B, Lönnerholm G, Osterman PO. Pyridostigmine in human breast milk. British Journal of Clinical Pharmacology 14: 565–567, 1982 ArticlePubMedCAS Google Scholar
Hartvig P, Wiklund L, Lindström B. Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. Acta Anaesthesiologica Scandinavica 30: 177–182, 1986 ArticlePubMedCAS Google Scholar
Holmstedt B. The ordeal bean of old calabar: the pageant of physostigma venenosum in medicine. In Swain (Ed.) Plants in the development of modern medicine, pp. 303–360, Harvard University Press, Cambridge, Massachusetts, 1972 Google Scholar
Husain MA, Roberts JB, Thomas BH, Wilson A. Metabolism and excretion of 3-hydroxyphenyltrimethylammonium and neostigmine. British Journal of Pharmacology 35: 344–350, 1969 ArticlePubMedCAS Google Scholar
Jewsbury JM. Metrifonate in schistosomiasis — therapy and prophylaxis. Acta Pharmacologica et Toxicologica 49 (Suppl. V): 123–130, 1981 PubMed Google Scholar
Kark RAP, Rodriguez-Budelli M, Blass JP, Spence MA. Oral physostigmine and inherited ataxias. In Davis & Berger (Eds) Brain acetylcholine and neuropsychiatric disease, pp. 143–153, Plenum Press, New York and London, 1979 Chapter Google Scholar
Kleinwächter. Beobachtung über die Wirkung des Calabar-Extracts gegen Atropinvergiftung. Berliner Klinische Wochenschrift 369–371, 1864 Google Scholar
Kornfeld P, Mittag TN, Genkins G, Horowitz S, Papatestas AE. Studies in myasthenia gravis. Pyridostigmine-l4C metabolism after thymectomy. Neurology 25: 998–999, 1975 ArticlePubMedCAS Google Scholar
Kornfeld P, Samuels AJ, Wolf RL, Osserman KE. Metabolism of l4C-labeled pyridostigmine in myasthenia gravis. Evidence for multiple metabolites. Neurology 20: 634–640, 1970 ArticlePubMedCAS Google Scholar
Kornfeld P, Wolf RL, Samuels AJ, Osserman KE. The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis. Neurology 21: 530–532, 1971 Article Google Scholar
Kunze H, Blime K, Vogt W. Intestinal absorption of a mono-quaternary drug l4C-neostigmine. Naunyn Schmiedeberg’s Archives of Pharmacology 270: 161–168, 1971 ArticleCAS Google Scholar
Laqueur L. Über Atropin und Physostigmin in ihre Wirkung auf den intraocularen Druck. Ein Beitrag zur Therapie des Glaucoms. Albert von Graefes Archiv der Ophthalmologie 23: 149–176, 1877 Google Scholar
Mohs RC, Davis BM, Johns CA, Mathé AA, Greenwald BS, et al. Oral physostigmine treatment of patients with Alzheimer’s disease. American Journal of Psychiatry 142: 28–33, 1985 PubMedCAS Google Scholar
Miller RD, van Nyhuis LS, Eger EI, Vitez TS, Way WL. Comparative times to peak effect and durations of action on neostigmine and pyridostigmine. Anesthesiology 41: 27–33, 1974 ArticlePubMedCAS Google Scholar
Morris RB, Cronnelly R, Miller RD, Stanski D, Fahey MR. Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. Anesthesiology 54: 399–402, 1981 ArticlePubMedCAS Google Scholar
Nilsson E, Himberg J-J. Physostigmine for post-operative somnolence after diazepam-nitrous oxide anaesthesia. Acta Anaesthesiologica Scandinavica 26: 9–14, 1982 ArticlePubMedCAS Google Scholar
Nordgren I, Bengtsson E, Holmstedt B, Pettersson B-M. Levels of metrifonate and dichlorvos in plasma and erythrocytes during treatment of schistosomiasis with Bilarcil. Acta Pharmacologica et Toxicologica 49 (Suppl. 1): 79–86, 1981 PubMedCAS Google Scholar
Nordgren I, Bergström M, Holmstedt B, Sandoz M. Metrifonate and action of dichlorvos. Arch. Toxicol. 41: 31–41, 1978 ArticlePubMedCAS Google Scholar
Nordgren I, Holmstedt B, Bengtsson E, Finkel Y. Plasma levels of metrifonate and dichlorvos during treatment of schistosomiasis with Bilarcil. American Journal of Tropical Medicine and Hygiene 29: 426–430, 1980 PubMedCAS Google Scholar
Nowell PT, Scott CA, Wilson A. Determination of neostigmine and pyridostigmine in the urine of patients with myasthenia gravis. British Journal of Pharmacology 18: 617, 1962a CAS Google Scholar
Nowell PT, Scott CA, Wilson A. Hydrolysis of neostigmine by plasma cholinesterase. British Journal of Pharmacology and Chemotherapy 19: 498–502, 1962b PubMedCAS Google Scholar
Osserman KE. Myasthenia gravis, Grune & Stratton, New York and London, 1958 Google Scholar
Osserman KE, Kaplan LI. Rapid diagnostic test for myasthenia gravis: increased muscle strength without fasciculations after intravenous administration of edrophonium (Tensilon) chloride. J. Am. Med. Assoc. 150: 265, 1952 ArticlePubMedCAS Google Scholar
Osterman PO, Aquilonius S-M. Treatment of myasthenia gravis. Pharmacy International 6: 94–97, 1985 Google Scholar
Pal J. Physostigmin ein Gegengift des Curare. Zeitblatt der Physiologie 14: 255–258, 1900 Google Scholar
Pettersson J, Gordh TE, Hartvig P, Wiklund L. A double blind clinical trial of the analgesic effects of i.v. physostigmine on postoperative pain. Acta Anaesthesiologica Scandinavica, in press, 1986 Google Scholar
Pohlmann JLW, Cohan SL. Simplified detection of quaternary ammonium compounds by gas chromatography. Journal of Chromatography 131: 297–301, 1977 ArticlePubMedCAS Google Scholar
Remen L. Zur Pathogenese und Therapie der myasthenia gravis pseudoparalytica. Deutsche Zeitung der Nervenheilkunde 128: 66–78, 1932 Article Google Scholar
Schankeer LS, Solomon HH. Active transport of quaternary ammonium compounds into bile. American Journal of Physiology 204: 829–832, 1963 Google Scholar
Sharpless NS, Thal LJ. Plasma physostigmine concentrations after oral administration. Lancet 1: 1397–1398, 1985 ArticlePubMedCAS Google Scholar
Sitaram N, Gillin JC. Development and use of pharmacological probes of the CNS in man: Evidence of cholinergic abnormality in primary affective illness. Biological Psychiatry 15: 925–955, 1980 PubMedCAS Google Scholar
Somani SM, Chan K, Dehghan A, Calvey TN. Kinetics and metabolism of intramuscular neostigmine in myasthenia gravis. Clinical Pharmacology and Therapeutics 28: 66–68, 1980 Google Scholar
Somani SM, Roberts JB, Wilson A. Pyridostigmine metabolism in man. Clin. Pharmacol. Therap. 13: 393–399, 1972 CAS Google Scholar
Sörensen DS, Flacks H, Friis ML, Hvidberg EF, Paulson OB. Steady state kinetics of pyridostigmine in myasthenia gravis. Neurology 34: 1020–1024, 1984 ArticlePubMed Google Scholar
Taylor P. Anticholinesterase agents. In Goodman & Gilman (Eds) The pharmacological basis of therapeutics, 6th ed., p. 108, MacMillan, New York, 1980 Google Scholar
Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet 226: 1200–1201, 1934 Article Google Scholar
Weinstock M, Davidson JT, Rosin AJ, Schnieden H. Effect of physostigmine on morphine-induced postoperative pain and somnolence. Brit. J. Anaesth. 54: 429–433, 1982 ArticlePubMedCAS Google Scholar
Whelpton R. Analysis of plasma physostigmine concentrations by liquid chromatography. Journal of Chromatography 272: 216–220, 1983 ArticlePubMedCAS Google Scholar
White MC, De Silva P, Harvard CWH. Plasma pyridostigmine levels in myasthenia gravis. Neurology 31: 145–150, 1981 ArticlePubMedCAS Google Scholar
Williams NE, Calvey TN, Chan K. Clearance of neostigmine from the circulation during antagonism of neuromuscular block. British Journal of Anaesthesia 50: 1065–1067, 1978 ArticlePubMedCAS Google Scholar
Yakatan GJ, Tien J-Y. Quantitation of pyridostigmine in plasma using high performance liquid chromatography. Journal of Chromatography, Biomedical Applications 164: 399–403, 1979 ArticleCAS Google Scholar